106331-68-4

Basic information

• Product Name: 5,6-Dimethoxypicolinaldehyde
• Synonyms: 5,6-Dimethoxypicolinaldehyde;5,6-diMethoxypyridine-2-carboxaldehyde
• CAS NO: 106331-68-4
• Molecular Formula: C8H9NO3
• Molecular Weight: 167
• Mol File: 106331-68-4.mol

Chemical Properties

• Boiling Point: 257.7 °C at 760 mmHg
• Flash Point: 109.7 °C
• Appearance: /
• Density: 1.174 g/cm³
• Storage Temp.: 2-8°C
• PKA: 1.88±0.10(Predicted)
• CAS DataBase Reference: 5,6-Dimethoxypicolinaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6-Dimethoxypicolinaldehyde(106331-68-4)
• EPA Substance Registry System: 5,6-Dimethoxypicolinaldehyde(106331-68-4)

Safety Data

• Hazard Codes: Xn
• Statements: 22-41-43
• Safety Statements: 26-36/37
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 106331-68-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5,6-Dimethoxypicolinaldehyde is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, particularly in the area of medicinal chemistry.
Used in Medical Research:
5,6-Dimethoxypicolinaldehyde is used as a research tool in the field of medical research. Its properties and reactivity make it a valuable compound for studying biological processes and potential therapeutic applications.
Used in Chemical Synthesis:
5,6-Dimethoxypicolinaldehyde is used as a reagent in various chemical synthesis processes. Its versatility in forming different types of chemical bonds makes it a useful compound in the production of a wide range of chemical products.
Used in Commercial Industries:
5,6-Dimethoxypicolinaldehyde is used in the development of new materials and products in various commercial industries. Its unique properties and potential applications make it a valuable asset in the creation of innovative and effective solutions.

Upstream product

• 321535-37-9 2-bromo-6-iodo-3-methoxypyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 321535-23-3 2,3-dimethoxy-6-iodo-pyridine 

Downstream Products

• 59081-38-8 (5,6-dimethoxypyridin-2-yl)methanol 
• 882033-69-4 tert-butyl 3-[4-chloro-5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxypyrrolo[3,2-b]pyridine-1-carboxylate 
• 882033-59-2 tert-butyl 3-[5-fluoro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxy-pyrrolo[3,2-b]pyridine-1-carboxylate 
• 882033-48-9 t-Butyl 3-[4-chloro-1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-5,6-dimethoxypyrrolo[3,2-b]pyridine-1-carboxylate 
• 882033-37-6 t-butyl 5,6-dimethoxy-3-[1-(toluene-4-sulfonyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]pyrrolo[3,2-b]pyridine-1-carboxylate 
• 882033-34-3 3-bromo-5,6-dimethoxy-1H-pyrrolo[3,2-b]pyridine 
• 882033-33-2 5,6-dimethoxy-1H-pyrrolo[3,2-b]pyridine 

Relevant articles and documents

BCL-2 INHIBITOR

Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.

CHROMEN-4-ONE DERIVATIVES, SUCH AS E.G. FLAVONES, FOR USE AS CK2 INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATION

Chromen-4-one derivatives, such as e.g. flavone derivatives and pharmaceutical compositions thereof are disclosed. In some instances, the compounds have increased aqueous solubility, bioavailability, and ability to cross the blood-brain-barrier. The compounds may be used to inhibit casein kinase 2 (CK2) activity and/or to treat diseases and conditions mediated at least in part by CK2 enzyme, such as e.g. inflammation, in particular neuroinflammation, or other diseases, such as e.g. cancer, cardiac hypertrophy, cystic fibrosis, a neurodegenerative disease, bipolar disorder, depression, a viral infection, obesity, diabetes mellitus, atherosclerosis, epilepsy, or any combination thereof.

TRICYCLIC PIPERIDINE COMPOUNDS

The present invention relates to compounds of the formula (I) wherein R1a, R1b, R2, R3, (R4)n and ring (A) are as described in the description, to their preparation, to pharmaceutically acc

Design of potent IGF1-R inhibitors related to bis-azaindoles

From an azaindole lead, identified in high throughput screen, a series of potent bis-azaindole inhibitors of IGF1-R have been synthesized using rational drug design and SAR based on a in silico binding mode hypothesis. Although the resulting compounds produced the expected improved potency, the model was not validated by the co-crystallization experiments with IGF1-R.

Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors

Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.